AG
ATHE

Aperio Group’s Alterity Therapeutics ATHE Stock Holding History

Aperio Group’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-208
Closed -$27K – 1879
2014
Q3 		$27K Sell
208
-77
-27% -$10.3K ﹤0.01% 1732
2014
Q2 		$39K Sell
285
-1,517
-84% -$173K ﹤0.01% 1717
2014
Q1 		$303K Buy
+1,802
New +$996K ﹤0.01% 1614
2013
Q4 		– Sell
-945
Closed -$283K – 1106
2013
Q3 		$233K Buy
945
+452
+92% +$104K ﹤0.01% 1564
2013
Q2 		$69K Buy
+493
New +$66.9K ﹤0.01% 1616

Other funds holding ATHE

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CAM
Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Aperio Group's ATHE Position: Q4 2014 in Review

Aperio Group sold out of Alterity Therapeutics (ATHE) in Q4 2014, closing a stake of 208 shares — an estimated $27K sold.

Aperio Group first reported a position in ATHE in Q2 2013 and held it in 5 quarters. The position peaked at $303K in Q1 2014. 24 funds tracked by Wall St. Rank hold ATHE as of Q4 2014.

  • Aperio Group reported no remaining Alterity Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Aperio Group sold 208 Alterity Therapeutics shares in Q4 2014, an estimated $27K.
  • Aperio Group first reported a position in Alterity Therapeutics in Q2 2013 and held it in 5 quarters.
  • Aperio Group's Alterity Therapeutics position peaked at $303K in Q1 2014.
  • 24 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2014.

Based on Aperio Group's 13F filing for Q4 2014, filed 30 Jan 2015.